VASCULAR & INTERVENTIONAL RADIOLOGY

Iran J Radiol. 2023 January; 20(1):e129700.

https://doi.org/10.5812/iranjradiol-129700.

Published online 2023 March 29.

Research Article



Clinical Effectiveness of Ultrasound-Guided Biolaser Versus Ozone Therapy in Reducing Chronic Pain in Knee Osteoarthritis: A Three-Month Follow-Up Study

Saeed Keshmiri 💿¹, Meysam Velayati 💿² and Sirous Momenzadeh 💿^{3,*}

¹Department of Anesthesiology, School of Medicine, Bushehr University of Medical Sciences, Bushehr, Iran

²Department of Radiology, Akhtar Orthopedic Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

^{*} Corresponding author: Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Email: sirusmomenzadeh@gmail.com

Received 2022 August 19; Revised 2023 February 15; Accepted 2023 February 19.

Abstract

Background: Biolaser is an emerging technology, which has attracted the attention of many surgeons and specialists in different medical fields.

Objectives: This study aimed to evaluate the clinical effectiveness of ultrasound-guided biolaser radiation versus ozone therapy in reducing chronic pain in patients with knee osteoarthritis during a three-month follow-up.

Patients and Methods: Sixty patients referring to pain clinic of Shohadaye-Tajrish and Akhtar hospitals in 2017, were included in this randomized single-blind clinical trial study. According to a randomized table of numbers, in Biolaser group (n = 30): 10 mL of normal saline + 5 mL of lidocaine 1% + BioLaser + Physical Therapy and in the Ozone group (n = 30), received 10 mL Ozone (30 mic/mL) plus 5 mL lidocaine 1% + BioLaser placebo + Physical Therapy received. The patients were evaluated for pain using visual analog scale (VAS) and knee function with Knee injury and Osteoarthritis Outcome Score (KOOS) questioner. The patients were followed up 4 & 12 weeks and reviewed at weeks 12 after the injection by an observer who was unaware of the groups (IRCT20111121008146N15).

Results: Comparison of the mean age (56.8 ± 8.5 years in the biolaser group vs. 51.5 ± 5.4 years in the ozone therapy group; P=0.721) and body mass index (31.1 ± 3.4 kg/m² in the biolaser group vs. 30.5 ± 2.6 kg/m² in the ozone therapy group; P=0.214) did not indicate any significant differences between the two groups. The pain severity decreased significantly at different times in the biolaser and ozone therapy group s (P = 0.018). The knee pressure sensitivity score was 1.3 ± 0.5 in the biolaser group and 1.6 ± 0.4 in the ozone therapy group at 12 weeks post-treatment (P = 0.037). The knee circumference was also 35.6 ± 3.0 cm in the biolaser group and 39.7 ± 3.9 cm in the ozone therapy group at 12 weeks post-treatment (P = 0.032). The KOOS performance score was 46.9 ± 9.4 in the biolaser group and 49.3 ± 7.9 in the ozone therapy group (P = 0.187). Besides, the KOOS quality of life score was 10 ± 1.3 in the biolaser group and 10.4 ± 1.5 in the ozone therapy group (P = 0.586).

Conclusion: Biolaser therapy under ultrasound guidance was found to be a safe, non-invasive, and effective method, which could improve chronic pain in knee osteoarthritis during a three-month follow-up.

Keywords: Biolaser, Ozone, Ultrasound Guidance, Knee Osteoarthritis, Chronic Pain

1. Background

Knee osteoarthritis is a common cause of referral to clinics and one of the debilitating diseases with a good prognosis if treated surgically. However, surgery is not the method of choice for all patients with knee osteoarthritis because of surgical complications. Besides, no patient with osteoarthritis tends to undergo surgery (1). Therefore, early diagnosis and maintenance interventions are of great priority in these patients (2, 3).

Cartilage injury is the primary characteristic of osteoarthritis. As the tissue cartilage lacks blood vessels and neurons, the pain mechanism is complex in these patients, affecting the non-cartilage structures of the joint, including the synovium, bone, and soft tissue. Inflammation of the joint, change in cartilage, and bone turnover in the osteoarthritis process represent the potential important role of molecular mediators in the pain mechanism of osteoarthritis. The mechanism of pain in osteoarthritis constitutes the activation and distribution of local antiinflammatory mediators, such as prostaglandins and cytokinases, and is accompanied by tissue injury, which is affected by proteases (4).

Copyright © 2023, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Biological lasers were first introduced 20 years ago (5). Because of its potential applications in biomedicine and biological research, this method has recently received particular attention (6-10). Biolaser or biological laser is a new type of laser, embedded or placed in part of a biological hole or environment (10). In the rehabilitation and physiotherapy of these patients, biolaser radiation with wavelengths of 600 - 980 nm with a low/medium energy level, such as gallium arsenide (GaAs) or helium neon (HeNe), is used. The application of this method appears to be successful in the management of chronic or acute musculoskeletal pain.

In the last 50 years, laser therapy has been used at low red light wavelengths in in vitro, in vivo and human studies (infrared radiation at wavelengths of 660 - 900 nm). Biolaser is specifically used for the management of degenerative knee osteoarthritis. The efficacy of this method in cartilage formation (11), cartilage erosion (12), production of super oxide dismutase enzymes (12), stress protein levels (13), and chondrocyte proliferation (13) has been assessed in previous research. In these studies, osteoarthritis was induced by the injection of chemical agents into the capsular segment of mouse and rabbit knee joints. The biolaser method decreases the joint inflammation process (11), joint cartilage reproduction (12), and stress protein levels and improves the repair of cartilage degeneration (13); it also increases the number of cartilage cells and the thickness of joint cartilage (14). In a previous meta-analysis, the biolaser method could significantly improve pain, using a 2-4 week therapeutic regimen at an optimal dose (15).

Currently, the biolaser method is used for the management of joint, neural, and soft tissue disorders. Considering the less invasive nature of this method, the reduced need for non-steroidal anti-inflammatory drugs (NSAIDs) and other pain killers, and improvement of the physical function of the knee in patients with osteoarthritis, researchers are paying special attention to biolasers. However, there are discrepancies regarding the application of low-level biolasers in alleviating pain in patients with knee osteoarthritis. The present study, for the first time, aimed to evaluate the clinical effectiveness of ultrasound-guided biolasers versus ozone therapy in alleviating chronic pain in knee osteoarthritis during a three-month follow-up in an Iranian population.

2. Objectives

For the first time, this study aimed to evaluate the clinical effectiveness of ultrasound-guided biolaser versus ozone therapy in reducing chronic pain in knee osteoarthritis during a three-month follow-up in an Iranian population.

3. Patients and Methods

3.1. Study Population

This single-blind randomized clinical trial was conducted on patients with knee osteoarthritis, referred to the pain clinics of Shohadaye-Tajrish and Akhtar hospitals (Tehran, Iran) in 2017. The inclusion criteria were consent to participate in the study, age range of 40 years or above, pain due to knee osteoarthritis for more than three months, and radiological findings of osteoarthritis according to the American College of Rheumatology (ACR) (16). On the other hand, the exclusion criteria were as follows: A history of knee surgery; deformity or contracture of the lower limbs; neuromuscular disorders of the lower limbs; acute lumbar pathologies; recent intraarticular steroid injections in the past two months; history of inflammatory rheumatoid arthritis, infection, or diabetes; pregnancy; breastfeeding; body mass index (BMI) > 35 kg/m^2 ; being a candidate for knee surgery; genu varum or genu valgus $> 5^{\circ}$, confirmed by 3D images joint-view; radicular pain of the knee; use of anticoagulants; posttraumatic arthrosis; ozone therapy in the past 12 months; systemic or psychiatric disorders; and severe osteoarthritis (grade > III) (Figure 1).

Sixty participants were randomly assigned to ultrasound-guided biolaser and ozone therapy groups (n = 30 per group), according to a random number table (with a series of digits from 0 to 9, arranged randomly in rows and columns).

3.2. Intervention

The patients assigned to the ozone therapy group received 10 cc of ozone (30 μ g/mL), 5 mL of lidocaine 1%, placebo biolaser, and physical therapy (corrective exercise). The patients assigned to the biolaser group received 10 mL of normal saline, 5 mL of lidocaine 1%, and biolaser radiation plus physical therapy (corrective exercise). To perform the procedure, the patients were placed in the supine position, and the injection site landmarks were marked on the lateral side of the knee by flexing the knee by 30 - 45 degrees. The injection site was then disinfected with povidone-iodine. Using a 27-gauge needle, 2 mL of 2% lidocaine solution was injected, and the skin and joint surface were anesthetized. After aspiration and ensuring the correct placement of the needle, intraarticular ozone injection was performed under ultrasound guidance. Biolaser radiation was also carried out under ultrasound guidance.

Ozone injection was performed weekly for three weeks; the final dose was injected one month after the third dose. The participants received biolaser and placebo therapies three times a week (every other day, a total of 12 sessions). The patients were blinded to the intervention. Next, the injection site was disinfected, and for biolaser radiation (Prob 890 MJ, Thor Company, UK), 30 mV per point was



applied. For red and infrared superluminescent diodes (SLD), the knees were positioned on the lateral, medial, and popliteal sides. The therapeutic regimen involved three steps (Figure 2) (17):

(1) Red light radiation (660 nm) using a flexible gaala laser diode 180 sld system (750 mW).

(2) Infrared radiation (840 nm) using a flexible gaala laser diode 180 sld system (1500 mW).

(3) Using an infrared laser probe (830 nm) with a flexible gaala laser with a focused laser source on the basic pathology (75 - 200 mW).

For complete management of the knee circumference, each SLD was placed in three lateral, medial, and popliteal positions. To penetrate into the patellar and posterior patellar spaces, the knee was flexed to 90° (Figure 2) (17). In each session, radiation was performed on three points (lateral, upper, and lower points of the patella, with a maximum patellar edge of 3 cm). At each point, 8 J of energy (total energy, 32 J) was radiated with a laser probe. In the placebo laser group, radiation was performed using a non-active probe. The participants did not take any steroidal, antidepressant, or sedative medications.

Five variables, including pain, symptoms, daily activities, athletic and recreational activities, and knee-related quality of life, were measured based on the Knee injury and Osteoarthritis Outcome Score (KOOS) (18), which was completed by the patients before and three months after injecting the final dose. The pain severity was assessed us-



Figure 2. The knee is flexed to 90 degrees to penetrate into the patellar and posterior patellar spaces.

ing a visual analog scale (VAS), with scores ranging from 0 to 10. The participants were asked to score their pain severity before the intervention, one month after the intervention, and three months after the intervention. Sensitivity to pressure was measured by the Ritchie Articular Index (0 = "No pain"; 1 = "Patient complained of pain"; 2 = "Patient complained of pain and winced"; 3 = "Patient complained of pain, winced, and withdrew the joint") (19). Additionally, the knee circumference was measured by a physician. If any complication occurred during the study, it was recorded.

3.3. Statistical Analysis

Data were collected from the patients' medical records; the collected data from the follow-ups, interviews, and visits were recorded in datasheets. All data were entered into SPSS version 26 (IBM Corp., released in 2019., IBM SPSS Statistics for Windows, IBM Corp., Armonk, NY, USA). After examining the normal distribution of quantitative data by Kolmogorov-Smirnov test, quantitative variables were compared between the two groups using *t*-test, Mann-Whitney test, paired *t*-test, and repeated measures ANOVA. Categorical variables were also analyzed using chi-square test. The significant level was considered to be less than 0.05.

4. Results

The demographic characteristics of the ozone therapy and biolaser radiation groups are presented in Table 1.

Comparison of pain severity changes based on the VAS score before, four weeks, and 12 weeks after treatment between the two groups is shown in Figure 3. Changes in pain severity were significantly different between the two groups, which suggests significant pain improvement in the biolaser group (P = 0.018). Comparison of pain severity at different intervals is presented in Table 2. There was a significant difference between the two groups four weeks after the onset of treatment (P = 0.005).

Comparison of KOOS score changes between the two groups in different intervals (before treatment, four weeks after treatment, and 12 weeks after treatment) is shown in Figure 4 (P > 0.05). Figure 5 presents a comparison of the knee pressure sensitivity between the two groups before treatment, four weeks after treatment, and 12 weeks after treatment (P < 0.05), as well as the knee circumference before treatment, four weeks after treatment, and 12 weeks after treatment (P < 0.05). Moreover, comparison of KOOS scores between the two groups at four and 12 weeks posttreatment is shown in Table 3.

Table 4 presents a comparison of the knee sensitivity to pressure, as well as the knee circumference in different intervals between the groups.

No complication was attributed to the study procedures during the study.

5. Discussion

In the current study, the pain severity significantly reduced in both groups in different intervals. The knee function and knee-related quality of life showed significant improvements after four weeks of treatment; however, no significant improvement was observed 12 weeks after treatment. The knee function and knee-related quality of life were better in the biolaser radiation group compared to the ozone therapy group; nevertheless, no significant difference was found between the two groups. In the present study, knee sensitivity to pressure and knee circumference significantly reduced in the biolaser radiation group. These findings are consistent with several previous reports (15, 20, 21).

Low-level laser therapy may intensify the biological effects by increasing adenosine triphosphate (ATP) production in the cell mitochondria; these biological effects contribute to the regulation of transcription factors, as well

Table 1. Comparison of the Demographic Information of the Participants Between the Ozone Therapy and Biolaser Radiation Groups					
Variables	Biolaser radiation ^a (No = 30)	Ozone therapy ^a (No=30)	P-value		
Age (y)	56.8 ± 8.5	51.5 ± 5.4	0.721		
BMI (kg/m ²)	31.1±3.4	30.5 ± 2.6	0.214		
Sex			0.179		
Male	16 (53.3)	11 (36.7)			
Female	14 (46.7)	19 (63.3)			

Abbreviation: BMI, body mass index.

 $^{\rm a}$ Age and BMI are described as mean \pm SD or No. (%).



Figure 3. Comparison of pain severity changes between the groups at different intervals (P = 0.018).

as anti-apoptosis and pro-survival genes (22, 23). Biological events in the tissue induce protein synthesis, increase cellular migration and proliferation, and modulate regulatory cytokines, growth factors, inflammatory mediators, tissue oxygenation, and remodeling (24-26). Therefore, one of the most important clinical goals of low-level laser therapy is the management of tissue inflammation and degeneration.

Since osteoarthritis has a complex pathogenesis, red and infrared light radiation was performed at wavelengths of 660, 840, and 830 nm; these wavelengths were used for activation of different cellular pathways in several basic

Table 2. Comparison of Pain Severity Between the Ozone Therapy and Biolaser Radiation Groups at Different Intervals						
Variables	Biolaser radiation(No=30)	Ozone therapy(No=30)	P-value			
VAS score before	5.7± 0.6	5.7±1.0	0.262			
VAS score after four weeks	3.5 ± 0.4	3.3 ± 0.5	0.005			
VAS score after 12 weeks	2.6 ± 0.2	2.7± 0.6	0.160			
P-value (4 weeks vs. 12 weeks)	< 0.0001	< 0.0001				

Abbreviation: VAS, visual analog scale.



Figure 4. Comparison of Knee injury and Osteoarthritis Outcome Score (KOOS) score changes between the groups (P > 0.05).

and clinical studies (27-29). According to several reports, laser radiation at a wavelength of 660 nm leads to the electric stimulation of most biomolecules, such as cytochrome C oxidase (30-32). Previous reports show that laser radiation at a wavelength of 905 nm induces microthermal gradients and selective photothermolysis of mitochondria. Therefore, laser radiation at wavelengths of 660, 840, and 830 nm can be tolerated by cellular chromophores (22, 23).

In some studies, it was shown that the wavelengths used in the biolaser affect mitochondrial chromophores through photochemical reactions (23). Accordingly, a combination of 660, 840, and 830 nm wavelengths increases and strengthens the biological effects with high probability. Lievens and van der Veen. showed that a combination of laser wavelengths increases fibroblastic proliferation in cell injuries and produces better clinical results for the improvement of an injured connective tissue (33). Another study indicated the probable synergic effects of laser therapy at two different continuous wave and pulsed wavelengths in the management of peripheral nerve injuries

(<mark>34</mark>).

Biomolecular pathways are the target of all biological responses; consequently, wavelength is one of the important characteristics of laser therapy. Considering the photochemical reactions, red light radiation (660 nm) may target the mitochondria of cytochrome C oxidase, and infrared radiation (840 and 830 nm) initiates photochemical reactions in the lipid membranes of mitochondria. Accordingly, a combination of two or three wavelengths may improve the therapeutic effects of low-level laser therapy. The combination of photochemical and photophysical reactions in low-level laser therapy can also yield positive therapeutic results.

In conclusion, based on the present results, biolaser therapy under ultrasound guidance is a safe, non-invasive, and effective method that can improve chronic pain in knee osteoarthritis during a three-month follow-up. Therefore, application of the therapeutic biolaser protocol of the present study can be recommended to chronic pain specialists, orthopedic surgeons, and rheumatologists.



Figure 5. Comparison of Knee sensitivity to pressure and Knee circumference between the groups (P < 0.05).

Table 3. Comparison of KOOS Scores Between the Ozone Therapy and Biolaser Radiation Groups

Variables	Biolaser radiation (No=30)	Ozone therapy (NO = 30)	P-value
KOOS pain after four weeks	68.1±10.9	69.7±11.8	0.339
KOOS pain after 12 weeks	69.5 ± 10.3	69.6 ± 11.2	0.835
P-value	0.609	0.977	
KOOS symptoms after four weeks	59.3 ± 5.2	62.5 ± 4.4	0.015
KOOS symptoms after 12 weeks	59.5 ± 4.7	62.6 ± 4.4	0.011
P-value	0.150	0.159	
KOOS daily activities after four weeks	46.4 ± 9.7	49.2±7.9	0.164
KOOS daily activities after 12 weeks	46.9 ± 9.4	49.3 ± 7.9	0.187
P-value	0.183	0.161	
KOOS athletic and recreational activities after four weeks	13.4 ± 1.7	13.9 ± 1.8	0.349
KOOS athletic and recreational activities after 12 weeks	13.3 ± 1.6	13.9 ± 1.8	0.210
P-value	0.876	0.161	
KOOS quality of life after four weeks	10.2 ± 1.4	10.3 ± 1.4	0.516
KOOS quality of life after 12 weeks	10.3 ± 1.3	10.4 ± 1.5	0.586
P-value	0.293	0.161	

Abbreviation: KOOS, Knee injury and Osteoarthritis Outcome Score.

Footnotes

Authors' Contribution: Saeed Keshmiri: Sampling and treatment and follow-up and writing. Meysam Velayati: Design, methodologist, writing, interventional radiology. Sirous Momenzadeh: Design, methodologist, writing.

Clinical Trial Registration Code: The clinical trial registration code of this study is IRCT20111121008146N15.

Conflict of Interests: The authors declare no conflicts of interest.

Ethical Approval: This study adhered to the Declara-

Variables	Biolaser radiation (No = 30)	Ozone therapy (No = 30)	P-value
Knee sensitivity to pressure (before treatment)	2.5 ± 0.6	2.2 ± 0.9	0.043
Knee sensitivity to pressure (four weeks after treatment)	1.8 ± 0.6	1.4 ± 0.5	0.010
P-value	0.0001	0.0001	
Knee sensitivity to pressure (four weeks after treatment)	1.8 ± 0.6	1.4 ± 0.5	0.010
Knee sensitivity to pressure (12 weeks after treatment)	1.3 ± 0.5	1.6 ± 0.4	0.037
P-value	0.022	0.022	
Knee circumference (before treatment)	42.0 ± 3.2	40.6 ± 4.2	0.325
Knee circumference (four weeks after treatment)	41.6 ± 3.0	39.6 ± 4.0	0.037
P-value	0.010	0.002	
Knee circumference (four weeks after treatment)	41.6 ± 3.0	39.6 ± 4.0	0.032
Knee circumference (12 weeks after treatment)	35.6 ± 3.0	39.7±3.9	0.032
P-value	0.0001	0.161	

tion of Helsinki protocols, under the ethical approval code, IR.SBMU.RETECH.REC.1396.648.

Funding/Support: No funding was received for this study.

Informed Consent: Informed consent was obtained from the patients.

References

- Watterson JR, Esdaile JM. Viscosupplementation: therapeutic mechanisms and clinical potential in osteoarthritis of the knee. J Am Acad Orthop Surg. 2000;8(5):277-84. [PubMed ID: 11029555]. https://doi.org/10.5435/00124635-200009000-00001.
- Buckwalter JA, Stanish WD, Rosier RN, Schenck RJ, Dennis DA, Coutts RD. The increasing need for nonoperative treatment of patients with osteoarthritis. *Clin Orthop Relat Res.* 2001;(385):36–45. [PubMed ID: 11302324]. https://doi.org/10.1097/00003086-200104000-00008.
- 3. Leslie M. Knee osteoarthritis management therapies. *Pain Manag Nurs.* 2000;1(2):51-7. [PubMed ID: 11706459]. https://doi.org/10.1053/jpmn.2000.7782.
- Sofat N, Ejindu V, Kiely P. What makes osteoarthritis painful? The evidence for local and central pain processing. *Rheuma-tology (Oxford)*. 2011;50(12):2157-65. [PubMed ID: 21954151]. https://doi.org/10.1093/rheumatology/ker283.
- 5. Hänsch TW. Edible lasers and other delights of the 1970s. *Opt. Photonics News*. 2005;**16**:14–6.
- Gourley PL. Semiconductor microlasers: a new approach to cellstructure analysis. Nat Med. 1996;2(8):942–4. [PubMed ID: 8705868]. https://doi.org/10.1038/nm0896-942.
- Wang L, Liu D, He N, Jacques SL, Thomsen SL. Biological laser action. Appl Opt. 1996;35(10):1775–9. [PubMed ID: 21085301]. https://doi.org/10.1364/AO.35.001775.
- Sun Y, Shopova SI, Wu CS, Arnold S, Fan X. Bioinspired optofluidic FRET lasers via DNA scaffolds. *Proc Natl Acad Sci U S A*. 2010;**107**(37):16039– 42. [PubMed ID: 20798062]. [PubMed Central ID: PMC2941270]. https://doi.org/10.1073/pnas.1003581107.
- 9. Yun SH; Gather MC. Single-cell biological lasers. Nat. Photon. 2011;5:406-10.
- Fan X, Yun SH. The potential of optofluidic biolasers. Nat Methods. 2014;11(2):141-7. [PubMed ID: 24481219]. [PubMed Central ID: PMC4162132]. https://doi.org/10.1038/nmeth.2805.
 Pfander D, Jorgensen B, Rohde E, Bindig U, Muller G, Eric Scheller
- Pfander D, Jorgensen B, Rohde E, Bindig U, Muller G, Eric Scheller E. [The influence of laser irradiation of low-power density on an ex-

perimental cartilage damage in rabbit knee-joints: an in vivo investigation considering macroscopic, histological and immunohistochemical changes]. *Biomed Tech (Berl)*. 2006;**51**(3):131-8. [PubMed ID: 16961456]. https://doi.org/10.1515/BMT.2006.022.

- Cho HJ, Lim SC, Kim SG, Kim YS, Kang SS, Choi SH, et al. Effect of low-level laser therapy on osteoarthropathy in rabbit. *In Vivo*. 2004;18(5):585–91. [PubMed ID: 15523898].
- Lin YS, Huang MH, Chai CY, Yang RC. Effects of helium-neon laser on levels of stress protein and arthritic histopathology in experimental osteoarthritis. *Am J Phys Med Rehabil*. 2004;83(10):758–65. [PubMed ID: 15385784]. https://doi.org/10.1097/01.phm.0000137310.15943.19.
- Bayat M, Ansari A, Hekmat H. Effect of low-power helium-neon laser irradiation on 13-week immobilized articular cartilage of rabbits. *Indian J Exp Biol.* 2004;42(9):866-70. [PubMed ID: 15462178].
- Bjordal JM, Johnson MI, Lopes-Martins RA, Bogen B, Chow R, Ljunggren AE. Short-term efficacy of physical interventions in osteoarthritic knee pain. A systematic review and meta-analysis of randomised placebo-controlled trials. *BMC Musculoskelet Disord*. 2007;8:51. [PubMed ID: 17587446]. [PubMed Central ID: PMC1931596]. https://doi.org/10.1186/1471-2474-8-51.
- Suppiah R, Robson JC, Grayson PC, Ponte C, Craven A, Khalid S, et al. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. *Arthritis Rheumatol.* 2022;74(3):400–6. [PubMed ID: 35106973]. https://doi.org/10.1002/art.41983.
- 17. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. *Q J Med.* 1968;**37**(147):393-406. [PubMed ID: 4877784].
- Ebrahimi N, Jalaie S, Salsabili N, Ansari NN, Naghdi S. Knee Injury and Osteoarthritis Outcome Score in patients with isolated meniscus injury; Validity and reliability. J Res Med Sci. 2017;22:55. [PubMed ID: 28567074]. [PubMed Central ID: PMC5426089]. https://doi.org/10.4103/jrms.JRMS_941_16.
- Smith HR, Brown A. Rheumatoid arthritis: Rheumatoid Arthritis (RA) Clinical Presentation. Medscape Medical News. 2022. Available from: https://emedicine.medscape.com/article/331715-overview.
- Hegedus B, Viharos L, Gervain M, Galfi M. The effect of low-level laser in knee osteoarthritis: a double-blind, randomized, placebo-controlled trial. *Photomed Laser Surg.* 2009;27(4):577–84. [PubMed ID: 19530911]. [PubMed Central ID: PMC2957068]. https://doi.org/10.1089/pho.2008.2297.
- 21. Kahn F. Low intensity laser therapy: the clinical approach. Proc. of SPIE 6140.2006.

- Chen AC, Arany PR, Huang YY, Tomkinson EM, Sharma SK, Kharkwal GB, et al. Low-level laser therapy activates NF-kB via generation of reactive oxygen species in mouse embryonic fibroblasts. *PLoS One*. 2011;6(7). e22453. [PubMed ID: 21814580]. [PubMed Central ID: PMC3141042]. https://doi.org/10.1371/journal.pone.0022453.
- Moriyama Y, Nguyen J, Akens M, Moriyama EH, Lilge L. In vivo effects of low level laser therapy on inducible nitric oxide synthase. Lasers Surg Med. 2009;41(3):227-31. [PubMed ID: 19291752]. https://doi.org/10.1002/lsm.20745.
- 24. de Souza TO, Mesquita DA, Ferrari RA, Dos Santos Pinto DJ, Correa L, Bussadori SK, et al. Phototherapy with low-level laser affects the remodeling of types I and III collagen in skeletal muscle repair. *Lasers Med Sci.* 2011;26(6):803–14. [PubMed ID: 21761120]. https://doi.org/10.1007/s10103-011-0951-9.
- Yang Z, Wu Y, Zhang H, Jin P, Wang W, Hou J, et al. Low-level laser irradiation alters cardiac cytokine expression following acute myocardial infarction: a potential mechanism for laser therapy. *Photomed Laser Surg.* 2011;**29**(6):391–8. [PubMed ID: 21348574]. https://doi.org/10.1089/pho.2010.2866.
- Mesquita-Ferrari RA, Martins MD, Silva JJ, da Silva TD, Piovesan RF, Pavesi VC, et al. Effects of low-level laser therapy on expression of TNF-alpha and TGF-beta in skeletal muscle during the repair process. *Lasers Med Sci.* 2011;26(3):335–40. [PubMed ID: 21053039]. https://doi.org/10.1007/s10103-010-0850-5.
- Barolet D. Light-emitting diodes (LEDs) in dermatology. Semin Cutan Med Surg. 2008;27(4):227-38. [PubMed ID: 19150294]. https://doi.org/10.1016/j.sder.2008.08.003.
- 28. Hashmi JT, Huang YY, Osmani BZ, Sharma SK, Naeser MA, Hamblin

MR. Role of low-level laser therapy in neurorehabilitation. *PM R.* 2010;**2**(12 Suppl 2):S292–305. [PubMed ID: 21172691]. [PubMed Central ID: PMC3065857]. https://doi.org/10.1016/j.pmrj.2010.10.013.

- Hamblin MR. Mechanisms of low level light therapy. 2022. Available from: http://www.panaceaatlantic.com/sites/default/files/ HamblinReportHarvardMedical.pdf.
- Karu TI, Pyatibrat LV, Kolyakov SF, Afanasyeva NI. Absorption measurements of cell monolayers relevant to mechanisms of laser phototherapy: reduction or oxidation of cytochrome c oxidase under laser radiation at 632.8 nm. *Photomed Laser Surg.* 2008;26(6):593–9. [PubMed ID: 19099388]. https://doi.org/10.1089/pho.2008.2246.
- Kreslavski VD, Fomina IR, Los DA, Carpentier R, Kuznetsov VV, Allakhverdiev SI. Red and near infra-red signaling: hypothesis and perspectives. J Photochem Photobiol C: Photochem Rev. J Photochem Photobiol C: Photochem Rev. 2012;13(3):190–203.
- Houreld NN, Masha RT, Abrahamse H. Low-intensity laser irradiation at 660 nm stimulates cytochrome c oxidase in stressed fibroblast cells. *Lasers Surg Med.* 2012;44(5):429-34. [PubMed ID: 22488690]. https://doi.org/10.1002/lsm.22027.
- 33. Lievens P,, van der Veen P. Wound healing process: influence of LLLT on the proliferation of fibroblasts and on the lymphatic regeneration. 7th International Congress of European Medical Laser Association. 2000.
- 34. Gigo-Benato D, Geuna S, de Castro Rodrigues A, Tos P, Fornaro M, Boux E, et al. Low-power laser biostimulation enhances nerve repair after end-to-side neurorrhaphy: a double-blind randomized study in the rat median nerve model. *Lasers Med Sci.* 2004;**19**(1):57–65. [PubMed ID: 15316855]. https://doi.org/10.1007/s10103-004-0300-3.